Assay Report
Methods · Standard Curves · QC · Results
Develop de novo Electrochemiluminescence (ECL) assays for targets not in the V-PLEX or U-PLEX catalogs — including antibody screening and pairing, SULFO-TAG conjugation, assay optimization, and fit-for-purpose qualification — plus ELISA-to-ECL platform conversion for existing validated immunoassays.
Pre-configured V-PLEX and U-PLEX panels cover hundreds of analytes — but the human proteome has thousands. When your target is not in the catalog, R-PLEX builds a new MSD assay from the ground up: antibody pair screening and selection, SULFO-TAG conjugation (with documented label incorporation measured at 455 nm to avoid A280 interference), capture antibody spotting optimization on MULTI-ARRAY plates, and fit-for-purpose qualification. This is fundamentally different from U-PLEX configuration — U-PLEX assembles existing qualified antibodies into custom panels; R-PLEX creates new assays for targets with no existing MSD reagents. For laboratories with established ELISA assays, our ELISA-to-ECL conversion service transfers existing validated antibody pairs to the MSD format — gaining ECL's sensitivity (10–100×), wider dynamic range (3–4+ logs vs. 1–2), and multiplex compatibility while preserving your established reagent investment.
| U-PLEX (Configuration) | R-PLEX (Development) | |
|---|---|---|
| Target Must Be in Catalog? | Yes — linker-coupled antibodies must already exist | No — any target with suitable antibody pairs |
| Timeline | Days — antibodies assembled from inventory | 8–16 weeks — screening, pairing, optimization |
| What You Provide | Target list — we check catalog availability | Antibodies, or target protein for screening, or both |
| Assay Performance | Pre-characterized per individual target | Characterized during development — sensitivity, dynamic range, specificity documented |
| Cost Structure | Per-plex panel pricing | Milestone-based development fee + per-sample analysis |
| Multiplex Potential | 2–10 analytes per well | Custom target can be multiplexed with U-PLEX catalog analytes in future studies |
| Best For | Custom combinations of existing catalog analytes | Novel targets, PK/ADA assays, species-specific targets not in catalog, ELISA conversions |
R-PLEX is MSD's product name for de novo assay creation; it is distinct from U-PLEX panel configuration. All custom development is for research use.
Your validated capture antibody is immobilized on MSD MULTI-ARRAY plates (using MSD ELISA Conversion Packs for uncoated plate formats). Your detection antibody is conjugated with SULFO-TAG NHS-ester with documented label incorporation. Antibody specificity and affinity are preserved — the detection chemistry changes, not the binding reagents.
ECL conversion typically improves sensitivity 10–100× over colorimetric or fluorescent ELISA. The low background of electrical excitation (zero autofluorescence) and high binding capacity of the carbon electrode surface extend the lower limit of detection without changing the antibody pair. Dynamic range expands from 1–2 logs to 3–4+ logs.
Once converted, your custom assay can be multiplexed with V-PLEX or U-PLEX catalog analytes — enabling your target to be measured alongside standard biomarker panels from the same 25 µL sample well. Eliminates the platform-switching variability that would result from running ELISA and MSD on separate instruments.
| Item | Full Service | Notes |
|---|---|---|
| Feasibility Assessment | Complimentary | 1–2 week evaluation with project plan |
| SULFO-TAG & Biotin Conjugation | Included | With documented label incorporation (A455) |
| Assay Optimization | Included | Antibody concentrations, incubation, MRD, matrix |
| Fit-for-Purpose Qualification | Included | Precision, linearity, recovery, selectivity |
| Methods Documentation | Included | Full development report with QC criteria |
For Research Use Only. All development uses manufacturer-validated MSD reagents and documented protocols.
Provide target, available antibodies, and intended use context. We'll assess feasibility within 1–2 weeks.
Antibody screening, SULFO-TAG/biotin conjugation, assay optimization with milestone updates.
Receive your custom MSD assay with complete development documentation and QC performance data.
U-PLEX configures custom panels from existing, qualified, linker-coupled antibodies in the MSD catalog — it's a configuration exercise, not development. Timeline: days. R-PLEX develops new MSD assays for targets not in any catalog — full de novo development including antibody screening, SULFO-TAG conjugation, plate spotting optimization, and qualification. Timeline: 8–16 weeks. If your target is in the U-PLEX catalog, use U-PLEX. If it's not, R-PLEX is the path. R-PLEX is MSD's product name for de novo assay creation, distinct from U-PLEX configuration.
Yes. If you have validated antibody pairs from existing ELISA or other immunoassay platforms, our ELISA-to-ECL conversion service transfers them to the MSD format — capture antibody immobilized on MULTI-ARRAY plates (using MSD ELISA Conversion Packs), detection antibody conjugated with SULFO-TAG. This preserves your reagent investment while gaining ECL's sensitivity (10–100× improvement), wider dynamic range, and multiplex compatibility. For R-PLEX development where antibody pairs are not yet identified, we can screen candidate antibodies or work with recombinant target protein to identify suitable pairs. Contact us with your antibody specifications for technical feasibility assessment.
SULFO-TAG label incorporation is measured by absorbance at 455 nm — not at 280 nm, because SULFO-TAG absorbs significantly at 280 nm and interferes with standard A280 protein measurements. Protein concentration of the conjugate is determined by BCA assay with IgG standards. For biotin label incorporation on the capture antibody, the goal is typically 2–4 biotin labels per antibody — sufficient for stable streptavidin-plate immobilization without steric hindrance of antigen binding. For SULFO-TAG on the detection antibody, we optimize the challenge ratio (typically starting at 12:1 SULFO-TAG:antibody) to maximize signal without causing antibody aggregation or non-specific binding. These conjugation quality metrics are documented in the development report.
R-PLEX development follows a milestone-based structure: Phase 1 — Feasibility Assessment: 1–2 weeks, complimentary. Phase 2 — Antibody Screening & Conjugation: 4–8 weeks depending on whether suitable antibodies are already available or require screening. Phase 3 — Optimization & Qualification: 3–6 weeks including precision, linearity, recovery, and selectivity testing in relevant matrix. Total: 8–16 weeks from project initiation to qualified assay, target-dependent. ELISA conversion is typically faster (4–8 weeks) since antibody pairs are already validated. Cost is milestone-based — you commit to each phase after reviewing the previous phase's results. Contact us with your target details for a project-specific timeline and cost estimate.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×